| 英文名称 |
中文名称 |
CAS号 |
操作 |
| Thalidomide-piperazine-Boc |
1-Piperazinecarboxylic acid, 4-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-, 1,1-dimethylethyl ester |
2222114-64-7 |
详细
|
| Thalidomide 4'-ether-alkylC2-amine hydrochloride |
Thalidomide-linker 6 |
2341840-99-9 |
详细
|
| (S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride |
(S,R,S)-AHPC-PHENOL-C4-NH2 (DIHYDROCHLORIDE) |
2376990-26-8 |
详细
|
| Pomalidomide-PEG4-C-COOH |
E3 Ligase Ligand-Linker Conjugates 1 |
2097938-44-6 |
详细
|
| Thalidomide-Piperazine-PEG1-COOH |
|
2731007-11-5 |
详细
|
| Thalidomide-NH-PEG3-propionic acid |
Pomalidomide-PEG3-CO2H |
2138440-82-9 |
详细
|
| MRT00033659 |
|
1401731-54-1 |
详细
|
| ML401 |
|
1597489-14-9 |
详细
|
| EAI001 |
2-(1-氧代异吲哚啉-2-基)-2-苯基-N-(噻唑-2-基)乙酰胺 |
892772-75-7 |
详细
|
| GSK682753A |
1334294-76-6 |
1334294-76-6 |
详细
|
| NIBR189 |
|
1599432-08-2 |
详细
|
| EAI045 |
EAI-045 |
1942114-09-1 |
详细
|
| Simotinib |
|
944258-89-3 |
详细
|
| HLM006474 |
CS-1224 |
353519-63-8 |
详细
|
| Alflutinib mesylate |
AST2818甲磺酸盐 |
2130958-55-1 |
详细
|
| JND3229 |
|
2260886-64-2 |
详细
|
| Lapatinib ditosylate monohydrate |
二对甲苯磺酸拉帕替尼一水合物 |
388082-78-8 |
详细
|
| Nazartinib |
EGF816 |
1508250-71-2 |
详细
|
| Gefitinib-based PROTAC 3 |
|
2230821-27-7 |
详细
|
| BMS-690514 |
(3R,4R)-4-氨基-1-[[4-[(3-甲氧基苯基)氨基]吡咯并[2,1-F][1,2,4]三嗪-5-基]甲基]哌啶-3-醇 |
859853-30-8 |
详细
|
| AZ7550 Mesylate |
|
2319837-99-3 |
详细
|
| CP-724714 |
2-甲氧基-N-[3-[4-[[3-甲基-4-[(6-甲基-3-吡啶基)氧基]苯基]氨基]-6-喹唑啉基]-2-丙烯-1-基]乙酰胺 |
537705-08-1 |
详细
|
| TAS0728 |
|
2088323-16-2 |
详细
|
| ARRY-380 analog |
ARRY-380 |
937265-83-3 |
详细
|
| Zipalertinib |
齐帕勒替尼 |
1661854-97-2 |
详细
|
| (E/Z)-AG490 |
酪氨酸磷酸化抑制剂AG490 |
134036-52-5 |
详细
|
| EGFR-IN-11 |
|
2463200-44-2 |
详细
|
| PD168393 |
|
194423-15-9 |
详细
|
| Lazertinib |
拉泽替尼布 |
1903008-80-9 |
详细
|
| Almonertinib mesylate |
阿美替尼甲磺酸盐 |
2134096-06-1 |
详细
|
| 123C4 |
化合物123C4 |
2034159-30-1 |
详细
|
| Golgicide A-2 |
|
1394285-50-7 |
详细
|
| sEH inhibitor-7 |
化合物 SEH INHIBITOR-7 |
340221-20-7 |
详细
|
| Anti-inflammatory agent 35 |
化合物T64358 |
2293951-00-3 |
详细
|
| Antiviral agent 24 |
N6-(3-Trifluoromethylbenzyl)adenosine |
23661-03-2 |
详细
|
| AP-III-a4 |
|
1177827-73-4 |
详细
|
| OSI-420 free base |
2-[[4-[(3-乙炔基苯基)氨基]-7-(2-甲氧基乙氧基)-6-喹唑啉基]氧基]乙醇 |
183321-86-0 |
详细
|
| JWG-071 |
|
2250323-50-1 |
详细
|
| AG-1478 |
AG1478 |
153436-53-4 |
详细
|
| Pirodavir |
吡罗达韦 |
124436-59-5 |
详细
|
| AZD3759 |
|
1626387-80-1 |
详细
|
| RLX-33 |
|
2784577-71-3 |
详细
|
| Rupintrivir |
(2E,4S)-4-[(2R,5S)-2-(4-氟苄基)-6-甲基-5-(5-甲基异恶唑-3-基甲酰氨基)-4-氧代庚酰氨基]-5-[[(3S)-2-氧代-3-吡咯烷基]-2-戊烯酸乙酯 |
223537-30-2 |
详细
|
| XMD17-109 |
XMD17 109 |
1435488-37-1 |
详细
|
| Ravoxertinib |
GDC-0994 |
1453848-26-4 |
详细
|
| KO-947 |
|
1695533-89-1 |
详细
|
| ASTX029 |
ASTX-029 |
2095719-92-7 |
详细
|
| BAY885 |
BAY-885 |
2307249-33-6 |
详细
|
| PD153035 hydrochloride |
4-[(3-溴苯基)氨基]-6,7-二甲氧基喹啉 |
153436-54-5 |
详细
|
| FR 180204 |
FR180204 |
865362-74-9 |
详细
|
| BIX02188 |
(3Z)-3-[[[3-[(二甲基氨基)甲基]苯基]氨基]苯亚甲基]-2,3-二氢-2-氧代-1H-吲哚-6-甲酰胺 |
334949-59-6 |
详细
|
| Mutant EGFR inhibitor |
N-[5-[[5-氯-4-(1H-吲哚-3-基)-2-嘧啶基]氨基]-2-[[2-(二甲基氨基)乙基]甲基氨基]-4-甲氧基苯基]-2-丙烯酰胺 |
1421373-62-7 |
详细
|
| AST-1306 |
|
897383-62-9 |
详细
|
| AZD-9291 (Mesylate) |
AZD9291(甲磺酸盐) |
1421373-66-1 |
详细
|
| GSK2256294A |
SEH抑制剂(GSK2256294A) |
1142090-23-0 |
详细
|
| ERK1/2 inhibitor 1 |
|
2095719-90-5 |
详细
|
| Compound 56 |
N-(3-溴苯基)-6,7-二乙氧基-4-喹唑啉胺 |
171745-13-4 |
详细
|
| Pleconaril |
普可那利 |
153168-05-9 |
详细
|
| ONO-AE3-208 |
4-氰基-2-[[2-(4-氟-1-萘基)-1-氧代丙基]氨基]苯基丁酸 |
402473-54-5 |
详细
|
| AR-9281 |
1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea |
913548-29-5 |
详细
|
| Tizaterkib |
CS-2696 |
2097416-76-5 |
详细
|
| RG 13022 |
RG-13022 |
136831-48-6 |
详细
|
| Pioglitazone-d4 |
匹格列酮-D4 |
1134163-29-3 |
详细
|
| Ozagrel |
奥扎格雷 |
82571-53-7 |
详细
|
| FAPI-34 |
|
2374782-07-5 |
详细
|
| FAP-2286 |
FAP2286 |
2581741-18-4 |
详细
|
| PND-1186 |
PND1186 |
1061353-68-1 |
详细
|
| BI-4464 |
BI 4464) |
1227948-02-8 |
详细
|
| BMS-962212 |
|
1430114-34-3 |
详细
|
| Eugenol-d3 |
|
1335401-17-6 |
详细
|
| FIN56 |
|
1083162-61-1 |
详细
|
| URB597 |
|
546141-08-6 |
详细
|
| Ulixertinib (hydrochloride) |
BVD-523 盐酸盐 |
1956366-10-1 |
详细
|
| DY131 |
N'-(4-(二乙氨基)亚苄基)-4-羟基苯甲酰肼 |
95167-41-2 |
详细
|
| Ifebemtinib |
Ifebemtinib (BI-853520) |
1227948-82-4 |
详细
|
| Asundexian |
|
2064121-65-7 |
详细
|
| iFSP1 |
1-amino-3-(4-methylphenyl)pyrido[1,2-a]benzimidazole-2,4-dicarbonitrile |
150651-39-1 |
详细
|
| Pifithrin-β hydrobromide |
环状抑制剂-Α氢溴酸盐 |
511296-88-1 |
详细
|
| Alogliptin-d3 |
|
1133421-35-8 |
详细
|
| MB05032 |
2-氨基-5-异丁基-4-[5-膦酰基-2-呋喃基]噻唑 |
261365-11-1 |
详细
|
| Setanaxib |
2-(2-氯苯基)-4-[3-(二甲基氨基)苯基]-5-甲基-1H-吡唑并[4,3-C]吡啶-3,6(2H,5H)-二酮 |
1218942-37-0 |
详细
|
| UAMC-3203 hydrochloride |
|
2271358-65-5 |
详细
|
| Linagliptin |
利拉利汀 |
668270-12-0 |
详细
|
| Edoxaban tosylate |
伊多塞班对甲苯磺酸盐 |
480449-71-6 |
详细
|
| NADPH tetrasodium salt |
还原型辅酶Ⅱ四钠 |
2646-71-1 |
详细
|
| BI-3663 |
|
2341740-84-7 |
详细
|
| FAPI-46 |
|
2374782-04-2 |
详细
|
| Deferasirox |
地拉罗司 |
201530-41-8 |
详细
|
| GSK215 |
|
2743427-26-9 |
详细
|
| GPX4-IN-3 |
化合物 GPX4-IN-3 |
2761004-85-5 |
详细
|
| Defactinib |
地法替尼 |
1073154-85-4 |
详细
|
| GSK2256098 |
GSK-2256098 |
1224887-10-8 |
详细
|
| Erastin2 |
4(3H)-Quinazolinone, 2-[[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]methyl]-3-[4-(1-methylethoxy)[1,1'-biphenyl]-3-yl]- |
1695533-44-8 |
详细
|
| Dopamine-d5 (hydrochloride) |
盐酸多巴胺:(2 - (3 4-DIHYDROXYPHENYL) |
2193106-55-5 |
详细
|
| Lidocaine |
利多卡因 |
137-58-6 |
详细
|
| Darexaban |
N-[2-羟基-6-(4-甲氧基苯甲酰氨基)苯基]-4-(4-甲基-1,4-二氮杂庚烷-1-基)苯甲酰胺 |
365462-23-3 |
详细
|
| Pioglitazone |
匹格列酮 |
111025-46-8 |
详细
|
| LM22B-10 |
2-[[4-[[4-[BIS-(2-HYDROXYETHYL)-AMINO]-PHENYL]-(4-CHLORO-PHENYL)-METHYL]-PHENYL]-(2-HYDROXY-ETHYL)-AMINO]-ETHANOL |
342777-54-2 |
详细
|
| Conteltinib |
|
1384860-29-0 |
详细
|
| (rel)-AR234960 |
|
1408311-94-3 |
详细
|